• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    J&J’s Single-Dose COVID-19 Vax Issued EUA

    Icon to Acquire PRA Health Sciences

    Phlow Corp. and USP Form Alliance

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology

    Solid Dose Market Trends

    CatSci Opens New Site in UK
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Icon to Acquire PRA Health Sciences

    BMS Expands Cell Therapy Manufacturing Capabilities

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Emergent BioSolutions

    PCI Pharma Services

    Syngene

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    PCI Pharma Services

    Cytovance Biologics

    Flow Sciences

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    07 AbbVie

    ...

    07 AbbVie
    Abbvie made a bold strategic move to buy Allergan for approximately $63 billion in an effort to diversify its portfolio.
    Related CONTENT
    • AbbVie, I-Mab Enter Global Immuno-Oncology Alliance
    • AbbVie & Harvard University Form Research Alliance
    • Financial Report: Abbvie
    • FTC Clears AbbVie’s Acquisition of Allergan
    • Financial Report: Abbvie
    Kristin Brooks , Managing Editor, Contract Pharma07.15.20
    Headquarters: North Chicago, IL
    twitter.com/abbvie
    www.abbvie.com


    headcount:  30,000
    Year Established: 2013
    Revenues:  $33,266   (+2%)
    Net Income:  $7,882   (+39%)
    R&D:  $6,407  (-38%)

    TOP SELLING DRUGS   
    Drug Indication 2019 Sales (+/-%)
    Humira  rheumatoid arthritis  $19,169 -4%
    Imbruvica chronic lymphocytic leukemia   $3,830 29%
    Mavyret hepatitis C  $2,893  -16%
    Creon  cystic fibrosis $1,041 12%
    Leuplin prostate cancer  $887 -1%
    Venclexta  Leukaemia, chronic lymphocytic (CLL) $792 130%
    Synthroid hyperthyroidism  $786 1%
    Synagis  RSV $718 -1%
    Duopa Parkinson’s disease  $461 7%
    Skyrizi  psoriasis  $355 n/a

    In looking at AbbVie’s foreseeable growth drivers, in the first quarter of 2020 IMBRUVICA, VENCLEXTA, SKYRIZI continued to make strides. Revenues were up 10% in the quarter to $8.6 billion, despite a 15% decline in International Humira sales and a 29% drop in Mavyret sales, the company’s top sellers.

    AbbVie’s investments in its hematologic oncology portfolio are paying off, with global revenues of $1.5 billion in 1Q20, up 32% with IMBRUVICA revenues of $1.2 billion, up 21% and VENCLEXTA sales reaching $317 million. We’re also keeping an eye on new immunology assets SKYRIZI, with sales of $300 million, and RINVOQ, which had sales of $86 million in 1Q20. 

    The company is recouping some of the lost Humira revenues with improved treatment options in rheumatoid arthritis and psoriasis. SKYRIZI, an IL-23 inhibitor boasts a 75% improvement rate at week 16 in moderate to severe plaque psoriasis and RINVOQ, a new oral selective and reversible JAK inhibitor, improves signs and symptoms in rheumatoid arthritis patients through 72 and 84 weeks, as well as inhibits structural joint damage in rheumatoid arthritis patients. 

    Strategic Moves
    Last June AbbVie made a bold strategic move to buy Allergan for approximately $63 billion in an effort to diversify its portfolio, as the world’s best-selling drug, AbbVie’s flagship Humira, begins to feel the impact of biosimilar competition. Allergan brings the biggest name in medical aesthetics, Botox. The combined company will consist of several franchises with leadership positions across immunology, hematologic oncology, medical aesthetics, neuroscience, women's health, eye care and virology.

    The companies recently got the go ahead from the U.S. Federal Trade Commission (FTC) for AbbVie's pending acquisition of Allergan. AbbVie agreed to sell several assets to settle objections to its purchase Allergan, divesting Brazikumab and Zenpep.

    AstraZeneca will acquire brazikumab, an investigational IL-23 inhibitor in Phase IIb/III development for Crohn's Disease, and Phase II for ulcerative colitis. Nestle will acquire and take full operational ownership of Zenpep, a treatment available in the U.S. for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. Nestle also will be acquiring Viokace, another pancreatic enzyme preparation, as part of the deal.

    In another, albeit less sensational acquisition, AbbVie enhanced its early stage oncology pipeline with Seattle-based Mavupharma, a privately held biopharma company focused on new approaches to target the STING (STimulator of INterferon Genes) pathway to treat cancer. Mavupharma's lead candidate MAVU-104, is a first-in-class, orally active, small molecule inhibitor of ENPP1, an enzyme involved in the regulation of the STING pathway. Inhibiting ENPP1 with MAVU-104 allows for highly controlled enhancement of STING signaling in tumors without the need for injections. Enhancing STING signaling has shown promise in a variety of tumor models.

    R&D
    AbbVie gained several significant approvals for key growth products. The FDA and EMA approved RINVOQ (upadacitinib), a once-daily oral Janus kinase (JAK) inhibitor for the treatment of moderately to severely active rheumatoid arthritis (RA) in patients with an inadequate response or intolerance to methotrexate.

    Patients taking RINVOQ achieved clinical remission, a state characterized by almost no disease activity and symptoms, even without methotrexate.

    AbbVie also has applications under review for RINVOQ for the treatment of active psoriatic arthritis supported by studies demonstrating RINVOQ met the primary endpoint of response at week 12 versus placebo, as well as non-inferiority versus Humira in terms of response at week 12.

    In another big win, ORIAHNN recently became the first non-surgical, oral treatment option approved by the FDA for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, with a treatment duration of up to 24 months. Uterine fibroids are estrogen and progesterone-dependent non-cancerous tumors and are the most common type of benign tumor in women of reproductive age.

    Oncology Assets
    IMBRUVICA, in combination with rituximab, was approved by the FDA for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This milestone marks the 11th FDA approval for IMBRUVICA since it was first approved in 2013 and the sixth in CLL, the most common form of leukemia in adults.

    Also, the European Commission recently approved VENCLYXTO (venetoclax) in combination with obinutuzumab for patients with previously-untreated Chronic Lymphocytic Leukemia. Further, positive results from Phase III trial of VENCLEXTA (venetoclax) in combination with Azacitidine in patients with Acute Myeloid Leukemia (AML) demonstrated statistically significant improvement in the primary endpoints of overall survival and composite complete remission rate. AML is one of the most aggressive and difficult-to-treat blood cancers with a very low survival rate and few treatment options.

    Oncology Alliances
    AbbVie and Genmab recently partnered to develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates, and to research future differentiated antibody therapeutics for cancer. The companies will partner to develop Genmab's next-gen bispecific antibody programs, epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4 leveraging AbbVie's clinical expertise, antibody-drug conjugate (ADC) platform and global commercialization in hematological cancers.

    AbbVie is paying $750 million upfront and Genmab has the potential to receive as much as $3.15 billion in additional development, regulatory and sales milestones for all programs as well as royalties on sales for epcoritamab outside the U.S. and Japan. Except for these royalty-bearing sales, the companies will share profits on a 50:50 basis.

    A global, exclusive collaboration with Jacobio Pharmaceuticals aims to develop and commercialize SHP2 inhibitors targeting a key node in cancer and immune cells. SHP2 is a key protein mediator of cell signaling and many tumors have genetic mutations, driving abnormal cancer cell growth which rely on SHP2 activity. Jacobio's early clinical stage assets, JAB-3068 and JAB-3312, are oral small molecules designed to specifically inhibit SHP2 activity.

    SHP2 also plays a key role to control cytokine production and immune cell response and is believed to have dual effects by potentially reducing cancer cell growth and modulating immune responses to generate anti-tumor activities. 

    Expanding an alliance with Harpoon Therapeutics for HPN217, a B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC), the companies added up to six additional targets. These agreements are expected to advance and broaden the use of Harpoon’s TriTAC platform, which produces novel T cell engagers targeting both solid tumors and hematologic malignancies.  In a transaction valued at a potential $510 million in upfront, milestone payments, and royalties, AbbVie has an option to exclusive rights to HPN217.

    COVID-19 Efforts
    AbbVie is collaborating with select health authorities and institutions globally supporting the experimental use of the HIV medicine, Kaletra/Aluvia (lopinavir/ritonavir) to determine antiviral activity as well as efficacy and safety of lopinavir/ritonavir in treating COVID-19. 

    AbbVie is supporting clinical studies with lopinavir/ritonavir, working closely with European health authorities and the U.S. FDA, Centers for Disease Control and Prevention, National Institutes of Health and Biomedical Advanced Research and Development Authority to coordinate on these efforts. The company has also joined the Innovative Medicines Initiative to support research and discovery of targeted medicines against COVID-19. 
    Suggested For You
    AbbVie, I-Mab Enter Global Immuno-Oncology Alliance AbbVie, I-Mab Enter Global Immuno-Oncology Alliance
    AbbVie & Harvard University Form Research Alliance AbbVie & Harvard University Form Research Alliance
    Financial Report: Abbvie Financial Report: Abbvie
    FTC Clears AbbVie’s Acquisition of Allergan FTC Clears AbbVie’s Acquisition of Allergan
    Financial Report: Abbvie Financial Report: Abbvie
    Top Pharma M&A Deals of 2019 Top Pharma M&A Deals of 2019
    Harpoon, Abbvie Expand Immunotherapy Alliance Harpoon, Abbvie Expand Immunotherapy Alliance

    Related Top Companies Report

    • 25 CSL Behring

      25 CSL Behring

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 22 Astellas

      22 Astellas

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 21 Biogen

      21 Biogen

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20


    • 12 Amgen

      12 Amgen

      ...
      Tim Wright, Editor, Contract Pharma 07.20.20

    • 13 Gilead Sciences

      13 Gilead Sciences

      ...
      Kristin Brooks, Managing Editor 07.15.20

    • 10 Bristol-Myers Squibb

      10 Bristol-Myers Squibb

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.15.20


    • 03 Novartis

      03 Novartis

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 02 Roche

      02 Roche

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 09 Takeda

      09 Takeda

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 01 Pfizer, Inc.

      01 Pfizer, Inc.

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • The 2020 Top 25 Pharma and Biopharma Companies

      The 2020 Top 25 Pharma and Biopharma Companies

      Top 25 Pharma and Biopharma Companies (Based on 2019 Pharma/Biopharma Sales, in $U.S. Millions)
      Contract Pharma Staff 07.15.20

    • 08 GlaxoSmithKline

      08 GlaxoSmithKline

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 06 Sanofi

      06 Sanofi

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 05 Merck

      05 Merck

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 04 Johnson & Johnson

      04 Johnson & Johnson

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    Trending
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • Spark Therapeutics Appoints CTO
    • The Future Of Vaccines And Biologics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • J&J’s Single-Dose COVID-19 Vax Issued EUA
    • Icon to Acquire PRA Health Sciences
    • Phlow Corp. and USP Form Alliance
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Novo Nordisk Invests $80M in Tablet Production
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Martin Bauer Group Acquires Majority Stake in Beverage Company Power Brands
    Gencor Announces Positive Results in VeriSperse Bioavailability Study
    PanTheryx Inc. Acquires TruBiotics Brand from Bayer HealthCare LLC
    Coatings World

    Latest Breaking News From Coatings World

    Gelest CEO Elected to National Academy of Engineering
    PPG Appoints Tony Wu as VP, Automotive Refinish, Asia
    PPG Appoints John Bruno as VP, Investor Relations
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Axonics Buys Contura to Expand to Stress Urinary Incontinence
    Nurx Appoints Chief Medical Officer
    Median Technologies, UC San Diego to Partner on AI-Based Medical Imaging Technology
    Contract Pharma

    Latest Breaking News From Contract Pharma

    J&J’s Single-Dose COVID-19 Vax Issued EUA
    Icon to Acquire PRA Health Sciences
    Phlow Corp. and USP Form Alliance
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Universal Engraving Announces New President
    Raw Sugar Living Expands to Target with New Collection
    Supporting Female Beauty Brand Founders on International Women's Day
    Happi

    Latest Breaking News From Happi

    ACI and CBC Launch Webpage About ‘Quats’
    L’Occitane Launches Hand Cream Inspired by Women
    Kiehl’s Partners with Gyrl Wonder
    Ink World

    Latest Breaking News From Ink World

    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI analyzes pandemic's effect on label industry in new report
    UEI names Ross Hutchison president
    Schreiner MediPharm and AARDEX partner for clinical trials
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    U.S. Nonwovens Rebrands as Radienz Living
    What You’re Reading on Nonwovens-Industry.com
    Texas Medical Technology Partners with My Protect Kit
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Pandemic Pain: NuVasive's 2020 Sales Fall 10 Percent
    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login